The effect of CDK2 inhibitors on the proliferation of various cancer cells has been extensively studied, but less attention has been paid to the ability of CDK2 inhibitors to modulate the expression of transcription factors responsible for pluripotency. The gene discussed is CDK2; the disease is cancer.